Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista™ (oxycodone…

TORONTO, Feb. 02, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the U.S. Food and Drug Administration (“FDA“) has accepted for filing the Company’s previously-announced New Drug Application (“NDA”) seeking authorization to market (more…)

Intellipharmaceutics Submits New Drug Application for Rexista … – Nasdaq


TORONTO, Nov. 25, 2016 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has filed a New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA“) seeking authorization to market its Rexista® (more…)

US FDA approves Watson ANDA for Oxycodone and Acetaminophen tablets – Pharmaceutical…

US FDA has approved Watson Pharmaceuticals’ abbreviated new drug application (ANDA) for Oxycodone and Acetaminophen tablets, USP 7.5 mg/500 mg and 10 mg/650 mg.

The tablets are the generic equivalent to Endo Pharmaceuticals’ Percocet tablets to treat moderate to moderately severe pain.

The tablet will be manufactured at Watson’s Miami, Florida facility in US.

Headquartered in Corona, US, Watson Pharmaceuticals develops, manufactures and sells (more…)